4.6 Article

COVID-19 in lung transplant recipients-Risk prediction and outcomes

期刊

PLOS ONE
卷 16, 期 10, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0257807

关键词

-

资金

  1. PRACTIS Clinician Scientist Program of Hannover Medical School - German Research Foundation (DFG) [ME 3696/3-1]

向作者/读者索取更多资源

Patients after lung transplantation are at increased risk for life-threatening infections, including COVID-19. Studies on COVID-19 outcomes in this patient population are limited, but results show high mortality rates and hospitalizations. Survivors experience decline in exercise capacity and lung function, with stable anxiety, depression, and quality of life self-assessment. Charlson comorbidity index predicts mortality in these patients. Further research on long-term outcomes and impact on pre-existing CLAD are needed.
Patients after lung transplantation are at risk for life-threatening infections. Recently, several publications on COVID-19 outcomes in this patient population appeared, but knowledge on optimal treatment, mortality, outcomes, and appropriate risk predictors is limited. A retrospective analysis was performed in a German high-volume lung transplant center between 19th March 2020 and 18th May 2021. Impact of COVID-19 on physical and psychological health, clinical outcomes, and mortality were analyzed including follow-up visits up to 12 weeks after infection in survivors. Predictive parameters on survival were assessed using univariate and multivariate proportional hazards regression models. Out of 1,046 patients in follow-up, 31 acquired COVID-19 during the pandemic. 12 of 31 (39%) died and 26 (84%) were hospitalized. In survivors a significant decline in exercise capacity (p = 0.034), TLC (p = 0.02), and DLCO (p = 0.007) was observed at follow-up after 3 months. Anxiety, depression, and self-assessed quality of life remained stable. Charlson comorbidity index predicted mortality (HR 1.5, 1.1-2.2; p = 0.023). In recipients with pre-existing CLAD, mortality and clinical outcomes were inferior. However, pre-existing CLAD did not predict mortality. COVID-19 remains a life-threatening disease for lung transplant recipients, particularly in case comorbidities. Further studies on long term outcomes and impact on pre-existing CLAD are needed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据